Live Breaking News & Updates on Polpharma biologics

Stay informed with the latest breaking news from Polpharma biologics on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Polpharma biologics and stay connected to the pulse of your community

Pearce IP BioBlast w/e 02 Feb 2024

Regeneron announced that its marketing authorisation application (MAA) for linvoseltamab to treat adult patients with relapsed/refractory (R/R)…

Philippines , Germany , Denmark , Danish , Genentech-lucentis , Polpharma-biologics , Daiichi-sankyo , Daiichi-sankyo-biologics , Fresenius-kabi , Xbrane-biopharma , Genentech-actemra , Daiichi-sankyo-enhertu

Tysabri biosimilar Tyruko now available for adults with RRMS in Germany

Tysabri biosimilar Tyruko now available for adults with RRMS in Germany
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.

Germany , Rebecca-guntern , Polpharma-biologics , Novartis , European-commision , Eastern-europe , Antelope-phase ,

Sandoz launches Tyruko in Germany for treatment of adults with RRMS

Sandoz has announced the launch of Tyruko, a biosimilar to treat relapsing remitting multiple sclerosis (RRMS), in Germany.

Polpharma-biologics , Europe-rebecca-guntern , European-commission , Eastern-european ,

Sandoz Group: Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany

Sandoz Group: Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Switzerland , Germany , Swiss , Stefan-klotter , Chris-lewis , Karenm-king , Rebecca-guntern , Joerge-allgaeuer , Polpharma-biologics , Swiss-exchange-listing , European-commission , Biogen-ma-inc

Sandoz Launches First and Only Biosimilar for Multiple Sclerosis, Tyruko® (natalizumab), in Germany

Sandoz Launches First and Only Biosimilar for Multiple Sclerosis, Tyruko® (natalizumab), in Germany
koreabizwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from koreabizwire.com Daily Mail and Mail on Sunday newspapers.

Switzerland , Germany , Swiss , Joerge-allgaeuer , Polpharma-biologics , Karenm-king , Rebecca-guntern , Chris-lewis , European-commission , Swiss-exchange-listing , Biogen-ma-inc , Exchange-listing

Sandoz launches biosimilar for multiple sclerosis in Germany

Sandoz launches biosimilar for multiple sclerosis in Germany
financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.

Germany , Rebecca-guntern , Polpharma-biologics , European-commission , President-europe , Eastern-european ,

Sandoz To Launch Tyruko Biosimilar For Multiple Sclerosis In Germany On Feb. 1

(RTTNews) - Sandoz (SDZNY), a maker of generic and biosimilar medicines, announced Wednesday the launch of Tyruko (natalizumab) in Germany from Fe...

Germany , Rebecca-guntern , Polpharma-biologics , European-commission , More-such-health-news , President-europe ,

Kyverna Therapeutics Starts $100 Million IPO Effort (Pending:KYTX)

Kyverna Therapeutics Starts $100 Million IPO Effort (Pending:KYTX)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

United-states , American , Polpharma-biologics , Peter-maag , Bristol-myers-squibb , Westlake-biopartners , Johnson , Teva-pharmaceuticals , Vantage-market-research , Novartis , Gilead-sciences , Company-pipeline